Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Enanta Pharmaceuticals (United States) | Researchclopedia

Back to institutions

Enanta Pharmaceuticals (United States)

Watertown, Massachusettscompany

89

Works

6,066

Citations

41

h-index

Top Research Topics

Hepatitis C virus research Respiratory viral infections research Hepatitis B Virus Studies

Top Researchers

Martin Karplus Harvard University

979 works154,952 citationsh-index: 167

Recent Research

Discovery of a Potent and Selective KIT inhibitor for Treatment of Mast Cell-Mediated Diseases

Manuel Roqueta-Rivera,Tessa Cressey,et al.

20260 citations

Liver Disease Diagnosis and Treatment

Pneumonia and Respiratory Infections

HIV/AIDS drug development and treatment

Pneumocystis jirovecii pneumonia detection and treatment

Liver Diseases and Immunity

Antibiotic Resistance in Bacteria

Drug Transport and Resistance Mechanisms

Carbohydrate Chemistry and Synthesis

Chemical Synthesis and Analysis

Vlad Ratziu Inserm

690 works61,899 citationsh-index: 107

Olivier Michielin SIB Swiss Institute of Bioinformatics

493 works54,844 citationsh-index: 83

Zhi‐Gang Chen University of Science and Technology Liaoning

947 works49,631 citationsh-index: 114

Vincent Zoete SIB Swiss Institute of Bioinformatics

289 works41,736 citationsh-index: 60

Zhigang Chen Central South University

607 works31,572 citationsh-index: 85

EDP-978, a Potent KIT Inhibitor, Demonstrated Dose-dependent Target-Engagement and a Favorable Pharmacokinetic Profile with Once-Daily Dosing Potential in Humans

Lijuan Jiang,Yang Li,et al.

20260 citations

235. EDP-323, a First-in-Class, Oral, RSV-Specific, Non-Nucleoside L-Protein Inhibitor Antiviral Rapidly Reduces Total RSV Symptoms, Lower Respiratory Tract RSV Symptoms and Viral Load After Human Viral Challenge

John P. DeVincenzo,Alaa Ahmad,et al.

20260 citations

P-2181. Post-Exposure Prophylaxis (PEP) of Respiratory Syncytial Virus (RSV) Infection After High-Inoculum RSV Human Challenge: Analysis of a Randomized Double-Blind, Placebo-Controlled Trial of EDP-323, an Oral, Non-Nucleoside Polymerase Inhibitor Antiviral

John P. DeVincenzo,Alaa Ahmad,et al.

20260 citations

P-523. Zelicapavir (EDP-938) Antiviral Treatment is Associated with Shortened Duration of RSV Symptoms in a Randomized, Double-Blind, Placebo-Controlled, Clinical Trial in Children 28 Days to 36 Months of Age

Christopher E. Harris,John P. DeVincenzo,et al.

20260 citations

<scp>EDP</scp>‐323, a First‐In‐Class, Once‐Daily, Oral L‐Protein Inhibitor for the Treatment of <scp>RSV</scp>: Results From a Phase 1 Study in Healthy Adults

Kimberly Elmore,John P. DeVincenzo,et al.

20254 citations